| 前收市價 | 0.0500 |
| 開市 | 0.0495 |
| 買盤 | 0.0000 x 2900 |
| 賣出價 | 0.0000 x 1000 |
| 今日波幅 | 0.0360 - 0.0495 |
| 52 週波幅 | 0.0280 - 13.9300 |
| 成交量 | |
| 平均成交量 | 37,887 |
| 市值 | 939,648 |
| Beta 值 (5 年，每月) | 2.03 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -15.6400 |
| 業績公佈日 | 2024年4月22日 - 2024年4月27日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 10.00 |
Insider MonkeyHorizon Technology Finance Corporation (NASDAQ:HRZN) Q3 2023 Earnings Call Transcript
Horizon Technology Finance Corporation (NASDAQ:HRZN) Q3 2023 Earnings Call Transcript November 1, 2023 Operator: Greetings, and welcome to Horizon Technology Finance Corporation Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being […]
BenzingaEvelo Biosciences' Atopic Dermatitis Study Cohort Misses Primary Goal Again, Shuts Study, Lays Off More Staff
Evelo Biosciences Inc (NASDAQ: EVLO) said its fourth cohort of the EDP1815 Phase 2 trial in atopic dermatitis, consistent with the first three cohorts, failed to meet the primary endpoint of the proportion of patients who achieve an EASI-50 response at week 16. EASI-50 responses or greater were achieved at week 16 in 37.9% of patients dosed with EDP1815 versus 44.7% on placebo in the fourth cohort. Following the results, the company decided to cease further development of EDP1815 in atopic derma
